Estrella Immunopharma (ESLA) Operating Expenses (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Operating Expenses of $2.3 million for Q1 2026, up 8.92% year-over-year from $2.1 million in Q1 2025, and up 273.79% quarter-over-quarter from $613199.0 in Q4 2025.
Estrella Immunopharma (ESLA) Operating Expenses (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Operating Expenses for 6 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 8.92% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $13.3 million (down 29.32% YoY), while the FY2025 annual figure was $13.1 million, up 47.67% from the prior year.
- Operating Expenses improved to $2.3 million in Q1 2026 per ESLA's latest filing, from $613199.0 in the prior quarter.
- Across five years, Operating Expenses topped out at $8.4 million in Q1 2023 and bottomed at $120740.0 in Q1 2022.
- Historically, Operating Expenses has averaged $3.1 million across 5 years, with a median of $2.3 million in 2026.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 27343.83% — and 2024, when it tumbled 94.4%.
- Estrella Immunopharma's Operating Expenses stood at $5.6 million in 2022, then slumped by 81.91% to $1.0 million in 2023, then surged by 333.75% to $4.4 million in 2024, then sank by 86.15% to $613199.0 in 2025, then surged by 273.79% to $2.3 million in 2026.
- Business Quant data shows ESLA's Operating Expenses at $2.3 million in Q1 2026, $613199.0 in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.08 Mn |
| Mar 31, 2026 | 2.29 Mn |
| Dec 31, 2025 | 613,199.00 |
| Sep 30, 2025 | 4.80 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 469,530.00 |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 291,845.00 |
| Mar 31, 2023 | 8.38 Mn |
| Dec 31, 2022 | 5.64 Mn |
| Sep 30, 2022 | 2.89 Mn |
| Jun 30, 2022 | 399,765.00 |
| Mar 31, 2022 | 120,740.00 |
| Dec 31, 2021 | 164,100.00 |
| Sep 30, 2021 | 10,514.00 |